Literature DB >> 9645418

Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus.

M Funauchi1, S Ikoma, H Enomoto, A Horiuchi.   

Abstract

The proportion of the lymphocytes which produce the cytokines corresponding to murine T helper- (Th1) or Th2 cells was studied using flow cytometry in systemic lupus erythematosus (SLE). When the peripheral mononuclear cells were stimulated with phorbol myristate acetate and ionomycin in the presence of monensin, which blocks the secretion of cytokines, the positive rates for the cytoplasmic IL-2 and IFN-gamma were lower and those for the cytoplasmic IL-4 and IL-10 were higher in SLE than in normal subjects. When the cells were cultured with monensin alone, the positive rates for these 4 cytokines were slightly increased in SLE. These data suggest that the mononuclear cells are already activated in vivo and a deviation of the proportion of the Th cells to the Th2-like ones might be associated with the polyclonal B cell activation seen in SLE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645418     DOI: 10.1080/030097498440859

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  36 in total

1.  Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.

Authors:  M Dayan; R Segal; Z Sthoeger; A Waisman; N Brosh; O Elkayam; E Eilat; M Fridkin; E Mozes
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

2.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome.

Authors:  D I Mitsias; A G Tzioufas; C Veiopoulou; E Zintzaras; I K Tassios; O Kogopoulou; H M Moutsopoulos; G Thyphronitis
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

4.  Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus.

Authors:  Xu-yan Yang; Hui-ying Wang; Xiao-ying Zhao; Li-juan Wang; Qing-hua Lv; Qing-qing Wang
Journal:  J Clin Immunol       Date:  2013-02-23       Impact factor: 8.317

5.  Death-inducing receptors and apoptotic changes in lymphocytes of patients with heart transplant vasculopathy.

Authors:  H J Ankersmit; B Moser; S Roedler; I Teufel; A Zuckermann; G Roth; K Lietz; C Back; S Gerlitz; E Wolner; G Boltz-Nitulescu
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

6.  The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.

Authors:  Lee Ann Garrett-Sinha; Alyssa Kearly; Anne B Satterthwaite
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

7.  Association of interferon-gamma gene polymorphism (+874A) with arthritis manifestation in SLE.

Authors:  Marut Tangwattanachuleeporn; Pimpayao Sodsai; Yingyos Avihingsanon; Jongkonnee Wongpiyabovorn; Jeerapat Wongchinsri; Nattiya Hirankarn
Journal:  Clin Rheumatol       Date:  2007-08-23       Impact factor: 2.980

Review 8.  Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus.

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Francesco Silvestris
Journal:  J Biomed Biotechnol       Date:  2010-06-29

Review 9.  Cytokines in systemic lupus erythematosus.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

10.  T cell help is required to induce idiotypic-anti-idiotypic autoantibody network after immunization with complementary epitope 289-308aa of La/SSB autoantigen in non-autoimmune mice.

Authors:  M G Papamattheou; J G Routsias; E E Karagouni; C Sakarellos; M Sakarellos-Daitsiotis; H M Moutsopoulos; A G Tzioufas; E N Dotsika
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.